A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01740427
First received: November 26, 2012
Last updated: August 26, 2014
Last verified: August 2014
  Purpose

The study is designed to compare the clinical benefit following treatment with letrozole in combination with PD-0332991 versus letrozole in combination with placebo in postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.


Condition Intervention Phase
Breast Neoplasms
Drug: PD-0332991
Drug: Letrozole
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Multicenter, Double-Blind Phase 3 Study Of PD-0332991 (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Postmenopausal Women With ER (+), HER2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti Cancer Treatment For Advanced Disease

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Progression-Free Survival (PFS) [ Time Frame: Baseline up to 2.5 years ] [ Designated as safety issue: No ]
    Median time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.


Secondary Outcome Measures:
  • Probability of Participant Survival [ Time Frame: From start of study treatment up to 6 years ] [ Designated as safety issue: Yes ]
    Probability of survival 1-year, 2- and 3-years after the first dose of study treatment

  • Overall Survival (OS) [ Time Frame: Baseline to date of death from any cause (up to 6 years) ] [ Designated as safety issue: Yes ]
    Time from date of randomization to date of death due to any cause.

  • Objective Response (OR) [ Time Frame: Baseline up to 2.5 years ] [ Designated as safety issue: No ]
    OR is defined as a complete response (CR) or partial response (PR) according to RECIST v.1.1. recorded from randomization until disease progression or death due to any cause.

  • Duration of Response (DR) [ Time Frame: Baseline up to 2.5 years ] [ Designated as safety issue: No ]
    Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cancer.

  • Disease Control (DC) [ Time Frame: Baseline up to 2.5 years ] [ Designated as safety issue: No ]
    DC is defined as complete response (CR), partial response (PR), or stable disease (SD) ≥24 weeks according to the RECIST version 1.1 recorded in the time period between randomization and disease progression or death to any cause.

  • QTc interval [ Time Frame: Baseline and Day 14 of Cycle 1 ] [ Designated as safety issue: Yes ]
    Time between the start of the Q wave and the end of the T wave corrected for heart rate.

  • Minimum Observed Plasma Trough Concentration (Cmin) [ Time Frame: Day 14 of cycles 1 and 2 ] [ Designated as safety issue: No ]
    Minimum Observed Plasma Trough Concentration (Cmin)

  • Change From Baseline in Euro Quality of Life (EQ-5D)- Health State Profile Utility at Week X [ Time Frame: Baseline up to 2.5 years ] [ Designated as safety issue: No ]
    Instrument designed to assess health status in terms of a single index value or utility score.

  • Change From Baseline in Functional Assessment od Cancer therapy -Breast (FACT-B) at Week X [ Time Frame: Baseline up to 2.5 years ] [ Designated as safety issue: No ]
    Instrument designed to assess patient concerns relating to breast cancer

  • Tumor tissue biomarkers [ Time Frame: Baseline, 24 months ] [ Designated as safety issue: No ]
    Tumor tissue biomarkers will be analyzed to investigate possible associations with resistance/sensitivity to treatment with study drugs. Biomarkers that will be analyzed will be selected based on their known relevance to mechanisms involved in cell cycle regulation.


Estimated Enrollment: 650
Study Start Date: February 2013
Estimated Study Completion Date: October 2016
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PD-0332991 + Letrozole
PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
Drug: PD-0332991
PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Drug: Letrozole
Letrozole, 2.5mg, orally once daily (continuously)
Active Comparator: Placebo + Letrozole
Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
Drug: Placebo
Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Drug: Letrozole
Letrozole, 2.5mg, orally once daily (continuously)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult women with locoregionally recurrent or metastatic disease not amenable to curative therapy.
  • Confirmed diagnosis of ER positive breast cancer
  • No prior systemic anti-cancer therapy for advanced ER+ disease.
  • Postmenopausal women
  • Measurable disease as per Response Evaluation Criterion in Solid Tumors [RECIST] or bone-only disease
  • Eastern Cooperative Oncology Group [ECOG] 0-2
  • Adequate organ and marrow function
  • Patient must agree to provide tumor tissue

Exclusion Criteria:

  • Confirmed diagnosis of HER2 positive disease
  • Patients with advanced, symptomatic, visceral spread that are at risk of life threatening complication in the short term
  • Known uncontrolled or symptomatic CNS metastases
  • Prior (neo)adjuvant treatment with letrozole or anastrozole with DFI ≤ 12-months from completion of treatment.
  • Prior treatment with any CDK 4/6 inhibitor.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01740427

  Hide Study Locations
Locations
United States, California
Pfizer Investigational Site
Alhambra, California, United States, 91801
Pfizer Investigational Site
Anaheim, California, United States, 92806
Pfizer Investigational Site
Baldwin Park, California, United States, 91706
Pfizer Investigational Site
Bellflower, California, United States, 90706
Pfizer Investigational Site
Beverly Hills, California, United States, 90211
Pfizer Investigational Site
Fontana, California, United States, 92335
Pfizer Investigational Site
Fullerton, California, United States, 92835
Pfizer Investigational Site
Harbor City, California, United States, 90710
Pfizer Investigational Site
Irvine, California, United States, 92604
Pfizer Investigational Site
Irvine, California, United States, 92618
Pfizer Investigational Site
Los Angeles, California, United States, 90045
Pfizer Investigational Site
Los Angeles, California, United States, 90034
Pfizer Investigational Site
Los Angeles, California, United States, 90095
Pfizer Investigational Site
Los Angeles, California, United States, 90027
Pfizer Investigational Site
Los Angeles, California, United States, 90095-1772
Pfizer Investigational Site
Los Angeles, California, United States, 90017
Pfizer Investigational Site
Los Angeles, California, United States, 90095-7349
Pfizer Investigational Site
Panorama City, California, United States, 91402
Pfizer Investigational Site
Pasadena, California, United States, 91105
Pfizer Investigational Site
Porter Ranch, California, United States, 91326
Pfizer Investigational Site
Redondo Beach, California, United States, 90277
Pfizer Investigational Site
Riverside, California, United States, 92505
Pfizer Investigational Site
San Diego, California, United States, 92120
Pfizer Investigational Site
San Francisco, California, United States, 94115
Pfizer Investigational Site
San Luis Obispo, California, United States, 93401
Pfizer Investigational Site
San Marcos, California, United States, 92069
Pfizer Investigational Site
Santa Maria, California, United States, 93454
Pfizer Investigational Site
Santa Monica, California, United States, 90404
Pfizer Investigational Site
Stanford, California, United States, 94305
Pfizer Investigational Site
Valencia, California, United States, 91355
Pfizer Investigational Site
West Hills, California, United States, 91307
Pfizer Investigational Site
Westlake Village, California, United States, 91361
Pfizer Investigational Site
Woodland Hills, California, United States, 91365
United States, Colorado
Pfizer Investigational Site
Grand Junction, Colorado, United States, 81501
United States, Connecticut
Pfizer Investigational Site
New Haven, Connecticut, United States, 06510
Pfizer Investigational Site
Norwalk, Connecticut, United States, 06856
United States, District of Columbia
Pfizer Investigational Site
Washington, District of Columbia, United States, 20007-2197
United States, Florida
Pfizer Investigational Site
Deerfield, Florida, United States, 33442
Pfizer Investigational Site
Fleming Island, Florida, United States, 32003
Pfizer Investigational Site
Hollywood, Florida, United States, 33021
Pfizer Investigational Site
Jacksonville, Florida, United States, 32258
Pfizer Investigational Site
Jacksonville, Florida, United States, 32207
Pfizer Investigational Site
Jacksonville, Florida, United States, 32256
Pfizer Investigational Site
Jacksonville, Florida, United States, 32204
Pfizer Investigational Site
Miami, Florida, United States, 33136
Pfizer Investigational Site
Orlando, Florida, United States, 32806
Pfizer Investigational Site
Pembroke Pines, Florida, United States, 33028
Pfizer Investigational Site
Plantation, Florida, United States, 33324
Pfizer Investigational Site
St. Augustine, Florida, United States, 32086
United States, Georgia
Pfizer Investigational Site
Atlanta, Georgia, United States, 30308
Pfizer Investigational Site
Atlanta, Georgia, United States, 30322
Pfizer Investigational Site
Atlanta, Georgia, United States, 30303
Pfizer Investigational Site
Duluth, Georgia, United States, 30096
Pfizer Investigational Site
Lawrenceville, Georgia, United States, 30046
Pfizer Investigational Site
Marietta, Georgia, United States, 30060
Pfizer Investigational Site
Snellville, Georgia, United States, 30078
United States, Idaho
Pfizer Investigational Site
Coeur d'Alene, Idaho, United States, 83814
Pfizer Investigational Site
Post Falls, Idaho, United States, 83854
United States, Illinois
Pfizer Investigational Site
Danville, Illinois, United States, 61832
Pfizer Investigational Site
Effingham, Illinois, United States, 62401
Pfizer Investigational Site
Mattoon, Illinois, United States, 61938
Pfizer Investigational Site
Skokie, Illinois, United States, 60076
Pfizer Investigational Site
Urbana, Illinois, United States, 61801
United States, Kentucky
Pfizer Investigational Site
Louisville, Kentucky, United States, 40202
United States, Maryland
Pfizer Investigational Site
Baltimore, Maryland, United States, 21201
Pfizer Investigational Site
Bethesda, Maryland, United States, 20889-5600
United States, Michigan
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48109
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48100
United States, Minnesota
Pfizer Investigational Site
St. Louis Park, Minnesota, United States, 55426
United States, Mississippi
Pfizer Investigational Site
Corinth, Mississippi, United States, 38834
Pfizer Investigational Site
Southaven, Mississippi, United States, 38671
United States, Missouri
Pfizer Investigational Site
Ballwin, Missouri, United States, 63011
Pfizer Investigational Site
St. Louis, Missouri, United States, 63141
Pfizer Investigational Site
St. Louis, Missouri, United States, 63109
United States, Nebraska
Pfizer Investigational Site
Grand Island, Nebraska, United States, 68803
Pfizer Investigational Site
Hastings, Nebraska, United States, 68901
United States, Nevada
Pfizer Investigational Site
Henderson, Nevada, United States, 89074
Pfizer Investigational Site
Henderson, Nevada, United States, 89052
Pfizer Investigational Site
Las Vegas, Nevada, United States, 89128
Pfizer Investigational Site
Las Vegas, Nevada, United States, 89148
Pfizer Investigational Site
Las Vegas, Nevada, United States, 89169
United States, New York
Pfizer Investigational Site
Mount Kisco, New York, United States, 10549
Pfizer Investigational Site
Mt Kisco, New York, United States, 10549
Pfizer Investigational Site
New York, New York, United States, 10032
Pfizer Investigational Site
Stony Brook, New York, United States, 11794-8446
United States, Oregon
Pfizer Investigational Site
Portland, Oregon, United States, 97227
Pfizer Investigational Site
Portland, Oregon, United States, 97201-3098
Pfizer Investigational Site
Portland, Oregon, United States, 97213
Pfizer Investigational Site
Tualatin, Oregon, United States, 97062
United States, Tennessee
Pfizer Investigational Site
Memphis, Tennessee, United States, 38120
Pfizer Investigational Site
Memphis, Tennessee, United States, 38104
Pfizer Investigational Site
Nashville, Tennessee, United States, 37203
United States, Texas
Pfizer Investigational Site
Dallas, Texas, United States, 75246
Pfizer Investigational Site
Dallas, Texas, United States, 75231
Pfizer Investigational Site
El Paso, Texas, United States, 79915
Pfizer Investigational Site
El Paso, Texas, United States, 79939
Pfizer Investigational Site
El Paso, Texas, United States, 79902
Pfizer Investigational Site
Fort Worth, Texas, United States, 76177
Pfizer Investigational Site
Fortworth, Texas, United States, 76177
Pfizer Investigational Site
Houston, Texas, United States, 77030-4009
United States, Virginia
Pfizer Investigational Site
Blacksburg, Virginia, United States, 24060
Pfizer Investigational Site
Low Moor, Virginia, United States, 24457
Pfizer Investigational Site
Newport News, Virginia, United States, 23606
Pfizer Investigational Site
Norfolk, Virginia, United States, 23502
Pfizer Investigational Site
Roanoke, Virginia, United States, 24014
Pfizer Investigational Site
Salem, Virginia, United States, 24153
Pfizer Investigational Site
Virginia Beach, Virginia, United States, 23456
Pfizer Investigational Site
Winchester, Virginia, United States, 22601
Pfizer Investigational Site
Wytheville, Virginia, United States, 24382
United States, Washington
Pfizer Investigational Site
Kirkland, Washington, United States, 98034
Pfizer Investigational Site
Seattle, Washington, United States, 98109
Pfizer Investigational Site
Vancouver, Washington, United States, 98684
Pfizer Investigational Site
Vancouver, Washington, United States, 98683
United States, West Virginia
Pfizer Investigational Site
Morgantown, West Virginia, United States, 26506-9162
United States, Wisconsin
Pfizer Investigational Site
Madison, Wisconsin, United States, 53792
Australia, New South Wales
Pfizer Investigational Site
Darlinghurst, New South Wales, Australia, 2010
Pfizer Investigational Site
Port Macquarie, New South Wales, Australia, 2444
Pfizer Investigational Site
Waratah, New South Wales, Australia, 2310
Australia, Queensland
Pfizer Investigational Site
Auchenflower, Queensland, Australia, 4066
Pfizer Investigational Site
Nambour, Queensland, Australia, 4560
Pfizer Investigational Site
Wooloongabba, Queensland, Australia, 4102
Australia, South Australia
Pfizer Investigational Site
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Pfizer Investigational Site
Epping, Victoria, Australia, 3076
Pfizer Investigational Site
Parkville, Victoria, Australia, 3050
Pfizer Investigational Site
Richmond, Victoria, Australia, 3121
Pfizer Investigational Site
Ringwood East, Victoria, Australia, 3135
Pfizer Investigational Site
Shepparton, Victoria, Australia, 3630
Australia, Western Australia
Pfizer Investigational Site
Perth, Western Australia, Australia, 6000
Australia
Pfizer Investigational Site
Bendigo, Australia, VIC 3550
Belgium
Pfizer Investigational Site
Brussel, Belgium, 1090
Pfizer Investigational Site
Brussels, Belgium, 1200
Pfizer Investigational Site
Brussels, Belgium, 1000
Pfizer Investigational Site
Charleroi, Belgium, 6000
Pfizer Investigational Site
Leuven, Belgium, 3000
Pfizer Investigational Site
Liege 1, Belgium, 4000
Pfizer Investigational Site
Verviers, Belgium, 4800
Pfizer Investigational Site
Wilrijk, Belgium, 2610
Canada, Alberta
Pfizer Investigational Site
Calgary, Alberta, Canada, T2N 4N2
Pfizer Investigational Site
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
Pfizer Investigational Site
Surrey, British Columbia, Canada, V3V 1Z2
Pfizer Investigational Site
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Nova Scotia
Pfizer Investigational Site
Halifax, Nova Scotia, Canada, B3H 2Y9
Pfizer Investigational Site
Halifax, Nova Scotia, Canada, B3H 1V7
Canada, Ontario
Pfizer Investigational Site
London, Ontario, Canada, N6A 4L6
Pfizer Investigational Site
Newmarket, Ontario, Canada, L3Y2P9
Pfizer Investigational Site
Toronto, Ontario, Canada, M4N 3M5
Pfizer Investigational Site
Toronto, Ontario, Canada, M5B 1W8
Pfizer Investigational Site
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Pfizer Investigational Site
Montreal, Quebec, Canada, H3T 1M5
Pfizer Investigational Site
Montreal, Quebec, Canada, H3A 1A1
Pfizer Investigational Site
Montreal, Quebec, Canada, H4JIC5
Pfizer Investigational Site
Montreal, Quebec, Canada, H3T 1E2
Canada, Saskatchewan
Pfizer Investigational Site
Regina, Saskatchewan, Canada, S4T 7T1
Canada
Pfizer Investigational Site
Quebec, Canada, G1S 4L8
Czech Republic
Pfizer Investigational Site
Hradec Kralove, Czech Republic, 500 05
France
Pfizer Investigational Site
Toulouse, Cedex 9, France, 31059
Pfizer Investigational Site
Angers Cedex 9, France, 49933
Pfizer Investigational Site
Caen Cedex 5, France, 14076
Pfizer Investigational Site
Dijon Cedex, France, 21079
Pfizer Investigational Site
La Roche-Sur-Yon, France, 85025
Pfizer Investigational Site
Montpellier CEDEX 5, France, 34298
Pfizer Investigational Site
Nice cedex 2, France, 06189
Pfizer Investigational Site
Paris Cedex 05, France, 75248
Pfizer Investigational Site
Rennes, France, 35062
Pfizer Investigational Site
Saint-Cloud, France, 92210
Pfizer Investigational Site
St Herblain, France, 44805
Pfizer Investigational Site
Villejuif, France, 94805
Germany
Pfizer Investigational Site
Kiel, SH, Germany, 24105
Pfizer Investigational Site
Boeblingen, Germany, 71032
Pfizer Investigational Site
Dresden, Germany, 01307
Pfizer Investigational Site
Erlangen, Germany, 91054
Pfizer Investigational Site
Hamburg, Germany, 20246
Pfizer Investigational Site
Magdeburg, Germany, 39108
Pfizer Investigational Site
Mainz, Germany, 55131
Pfizer Investigational Site
Muenchen, Germany, 81675
Pfizer Investigational Site
Muenchen, Germany, 80336
Pfizer Investigational Site
Muenchen, Germany, 81337
Pfizer Investigational Site
München, Germany, 80637
Pfizer Investigational Site
Trier, Germany, 54290
Hungary
Pfizer Investigational Site
Budapest, Hungary, 1122
Pfizer Investigational Site
Budapest, Hungary, 1032
Pfizer Investigational Site
Gyor, Hungary, 9024
Pfizer Investigational Site
Nyiregyhaza, Hungary, 4400
Pfizer Investigational Site
Szeged, Hungary, 6720
Ireland
Pfizer Investigational Site
Cork, Ireland
Pfizer Investigational Site
Dublin, Ireland, Dublin 7
Pfizer Investigational Site
Dublin, Ireland, 9
Pfizer Investigational Site
Dublin, Ireland, 8
Pfizer Investigational Site
Dublin 4, Ireland
Pfizer Investigational Site
Galway, Ireland
Pfizer Investigational Site
Limerick, Ireland
Pfizer Investigational Site
Waterford, Ireland
Italy
Pfizer Investigational Site
Meldola, FC, Italy, 47014
Pfizer Investigational Site
Milano, Milan, Italy, 20141
Pfizer Investigational Site
Avellino, Italy, 83100
Pfizer Investigational Site
Bologna, Italy, 40138
Pfizer Investigational Site
Pisa, Italy, 56126
Pfizer Investigational Site
Roma, Italy, 00144
Pfizer Investigational Site
Sora (FR), Italy, 03039
Japan
Pfizer Investigational Site
Nagoya, Aichi, Japan
Pfizer Investigational Site
Kashiwa, Chiba, Japan
Pfizer Investigational Site
Sapporo, Hokkaido, Japan
Pfizer Investigational Site
Kita-adachi-gun, Saitama, Japan
Pfizer Investigational Site
Chuo-Ku, Tokyo, Japan
Pfizer Investigational Site
Chiba, Japan
Pfizer Investigational Site
Ehime, Japan
Pfizer Investigational Site
Fukuoka, Japan
Pfizer Investigational Site
Hiroshima, Japan
Pfizer Investigational Site
Iwate, Japan
Pfizer Investigational Site
Kagoshima, Japan
Pfizer Investigational Site
Kumamoto, Japan
Pfizer Investigational Site
Niigata, Japan
Pfizer Investigational Site
Osaka, Japan
Korea, Republic of
Pfizer Investigational Site
Goyang-si, Gyeonggi-do, Korea, Republic of, 410-769
Pfizer Investigational Site
Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707
Pfizer Investigational Site
Seodaemun-Gu, Seoul, Korea, Republic of, 120-725
Pfizer Investigational Site
Seoul, Korea, Republic of, 138-736
Pfizer Investigational Site
Seoul, Korea, Republic of, 110-744
Pfizer Investigational Site
Seoul, Korea, Republic of, 135-710
Poland
Pfizer Investigational Site
Gdańsk, Poland, 80-952
Pfizer Investigational Site
Otwock, Poland, 05-400
Pfizer Investigational Site
Zory, Poland, 44-240
Russian Federation
Pfizer Investigational Site
Kursk, Kursk Region, Russian Federation
Pfizer Investigational Site
Kuzmolovo, Leningrad region, Russian Federation, 188663
Pfizer Investigational Site
Kazan, Russian Federation, 420029
Pfizer Investigational Site
Moscow, Russian Federation, 115478
Pfizer Investigational Site
Moscow, Russian Federation, 143423
Pfizer Investigational Site
Omsk, Russian Federation, 644013
Pfizer Investigational Site
Omsk, Russian Federation, 644046
Pfizer Investigational Site
Ryazan, Russian Federation, 390011
Pfizer Investigational Site
Ryazan, Russian Federation, 390026
Pfizer Investigational Site
Saint-Petersburg, Russian Federation, 197022
Pfizer Investigational Site
St. Petersburg, Russian Federation, 195271
Pfizer Investigational Site
Ufa, Russian Federation, 450054
Spain
Pfizer Investigational Site
Badalona, Barcelona, Spain, 08916
Pfizer Investigational Site
Terrassa, Barcelona, Spain, 08227
Pfizer Investigational Site
Palma de Mallorca, Islas Baleares, Spain, 07010
Pfizer Investigational Site
Alcorcon, Madrid, Spain, 28922
Pfizer Investigational Site
Badajoz, Spain, 06080
Pfizer Investigational Site
Barcelona, Spain, 08035
Pfizer Investigational Site
Barcelona, Spain, 08036
Pfizer Investigational Site
Barcelona, Spain, 08003
Pfizer Investigational Site
Donostia- San Sebastian, Spain, 20014
Pfizer Investigational Site
Jaen, Spain, 23007
Pfizer Investigational Site
L'Hospitalet de Llobregat (Barcelona), Spain, 08908
Pfizer Investigational Site
La Coruna, Spain, 15009
Pfizer Investigational Site
La Laguna (Santa Cruz de Tenerife), Spain, 38320
Pfizer Investigational Site
Lleida, Spain, 25198
Pfizer Investigational Site
Madrid, Spain, 28040
Pfizer Investigational Site
Madrid, Spain, 28041
Pfizer Investigational Site
Madrid, Spain, 28033
Pfizer Investigational Site
Madrid, Spain, 28007
Pfizer Investigational Site
Madrid, Spain, 28050
Pfizer Investigational Site
Sevilla, Spain, 41009
Pfizer Investigational Site
Sevilla, Spain, 41013
Pfizer Investigational Site
Valencia, Spain, 46009
Taiwan
Pfizer Investigational Site
Taipei, ROC, Taiwan, 112
Pfizer Investigational Site
Taipei, Taiwan, 10449
Pfizer Investigational Site
Taipei, Taiwan, 106
Ukraine
Pfizer Investigational Site
Dnipropetrovsk, Ukraine, 49102
Pfizer Investigational Site
Kharkiv, Ukraine, 61070
Pfizer Investigational Site
Lviv, Ukraine, 79031
Pfizer Investigational Site
Makiivka, Ukraine, 86120
Pfizer Investigational Site
Sumy, Ukraine, 40005
Pfizer Investigational Site
Uzhgorod, Ukraine, 88000
Pfizer Investigational Site
Zaporizhzhya, Ukraine, 69040
United Kingdom
Pfizer Investigational Site
Maidstone, Kent, United Kingdom, ME16 9QQ
Pfizer Investigational Site
Withington, Manchester, United Kingdom, M20 4BX
Pfizer Investigational Site
Glasgow, Scotland, United Kingdom, G12 0YN
Pfizer Investigational Site
Sutton, Surrey, United Kingdom, SM2 5PT
Pfizer Investigational Site
Edinburgh, United Kingdom, EH4 2XU
Pfizer Investigational Site
London, United Kingdom, SE1 9RT
Pfizer Investigational Site
London, United Kingdom, W6 8RF
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01740427     History of Changes
Other Study ID Numbers: A5481008
Study First Received: November 26, 2012
Last Updated: August 26, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
breast cancer
postmenopausal women
estrogen-receptor positive
HER2 negative
locoregionally recurrent
metastatic
Palbociclib (PD-0332991)
PALOMA-2

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Letrozole
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Aromatase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 26, 2014